The Effects of Intrapatient Variability in Tacrolimus Concentration on Clinical Outcomes Immediately After Liver Transplantation
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Tacrolimus, a calcineurin inhibitor, is an immunosuppressant used in post-transplantation maintenance therapy. The drug has a narrow therapeutic range and requires periodic therapeutic drug monitoring. Although many studies have reported the effects of intrapatient variability of tacrolimus on survival, rejection, and complications in renal transplant recipients, very few studies have reported these effects in liver transplant recipients. The purpose of this study was to evaluate the effect of intrapatient variability of tacrolimus on clinical outcomes after liver transplantation. Methods: Intrapatient variability was calculated using individual, averaged tacrolimus concentrations. Patients were divided into two groups according to their median variability value: high-variability and low-variability groups. The rate of deviation from the therapeutic range, incidence of acute rejection, posttransplant diabetes, incidence of infection, and estimated glomerular filtration rate (eGFR) after transplantation were compared between the groups. Results: Of the total patients (n=82), the high-variability group (n=41) exhibited significantly greater deviation from the therapeutic range (65.92% vs. 56.84%; p<0.001). There was no significant difference in acute rejection or posttransplantation diabetes incidence or eGFR; however, the number of infection in the first 6 months was significantly lower in the low-variability group (0.4 vs. 0.9 times; p=0.039). Multiple linear regression analysis showed that the number of infection significantly increased as intrapatient variability increased (p=0.015). Conclusion: High intrapatient variability in tacrolimus concentrations was strongly associated with an increased frequency of deviation from the suggested therapeutic range and an increased number of infection.
Abstract
Background: Tacrolimus, a calcineurin inhibitor, is an immunosuppressant used in post-transplantation maintenance therapy. The drug has a narrow therapeutic range and requires periodic therapeutic drug monitoring. Although many studies have reported the effects of intrapatient variability of tacrolimus on survival, rejection, and complications in renal transplant recipients, very few studies have reported these effects in liver transplant recipients. The purpose of this study was to evaluate the effect of intrapatient variability of tacrolimus on clinical outcomes after liver transplantation. Methods: Intrapatient variability was calculated using individual, averaged tacrolimus concentrations. Patients were divided into two groups according to their median variability value: high-variability and low-variability groups. The rate of deviation from the therapeutic range, incidence of acute rejection, posttransplant diabetes, incidence of infection, and estimated glomerular filtration rate (eGFR) after transplantation were compared between the groups. Results: Of the total patients (n=82), the high-variability group (n=41) exhibited significantly greater deviation from the therapeutic range (65.92% vs. 56.84%; p<0.001). There was no significant difference in acute rejection or posttransplantation diabetes incidence or eGFR; however, the number of infection in the first 6 months was significantly lower in the low-variability group (0.4 vs. 0.9 times; p=0.039). Multiple linear regression analysis showed that the number of infection significantly increased as intrapatient variability increased (p=0.015). Conclusion: High intrapatient variability in tacrolimus concentrations was strongly associated with an increased frequency of deviation from the suggested therapeutic range and an increased number of infection.
참고문헌 (20)
- Pichlmayr R, "Three-year follow-up of the European Multicenter Tacrolimus(FK506)Liver Study", Transplant Proc, 29, pp.2499~2502 (1997)
- Moini M, "Review on immunosuppression in liver transplantation", World J Hepatol, 7, pp.1355~1368 (2015)
- Senft JD, "A retrospective comparison of mycophenolate mofetil with lowexposure cyclosporine versus standard cyclosporine therapy in de novo liver transplant patients", Ann Transplant, 20, pp.539~543 (2015)
- Taber DJ, "Tacrolimus trough concentration variability and disparities in african american kidney transplantation", Transplantation, 101, pp.2931~2938 (2017)
- Sapir-Pichhadze R, "Timedependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure", Kidney Int, 85, pp.1404~1411 (2014)
- Borra LC, "High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation", Nephrol Dial Transplant, 25, pp.2757~2763 (2010)
- Rodriguez-Peralvarez M, "Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and metaanalysis", Am J Transplant, 12, pp.2797~2814 (2012)
- Pollock-Barziv SM, "Variability in tacrolimus blood levels increases the risk of late rejection and graft loss after solid organ transplantation in older children", Pediatr Transplant, 14, pp.968~975 (2010)
- Whalen HR, "High intrapatient tacrolimus variability is associated with worse outcomes in renal transplantation using a low-dose tacrolimus immunosuppressive regime", Transplantation, 101, pp.430~436 (2017)
- O’Regan JA, "Tacrolimus trough-level variability predicts long-term allograft survival following kidney transplantation", J Nephrol, 29, pp.269~276 (2016)
- Shuker N, "A high intrapatient variability in tacrolimus exposure is associated with poor long-term outcome of kidney transplantation", Transpl Int, 29, pp.1158~1167 (2016)
- Ro H, "Impact of tacrolimus intraindividual variability and CYP3A5 genetic polymorphism on acute rejection in kidney transplantation", Ther Drug Monit, 34, pp.680~685 (2012)
- Van der Veer MAA, "High intrapatient variability in tacrolimus exposure is not associated with immune-mediated graft injury after liver transplantation", Transplantation, 103, pp.2329~2337 (2019)
- Rayar M, "High intrapatient variability of tacrolimus exposure in the early period after liver transplantation is associated with poor outcomes", Transplantation, 102, pp.e108~e114 (2018)
- Rodriguez-Peralvarez M, "Early tacrolimus exposure after liver transplantation: relationship with moderate", severe acute rejection and long-term outcome, 2013, pp.58, 262~270
- Goodall DL, "High intrapatient variability of tacrolimus levels and outpatient clinic nonattendance are associated with inferior outcomes in renal transplant patients", Transplant Direct, 3, pp.e192~ (2017)
- Emre S, "Treatment of tacrolimusrelated adverse effects by conversion to cyclosporine in liver transplant recipients", Transpl Int, 13, pp.73~78 (2000)
- Agarwala S, "Evaluation of renal function in transplant patients on tacrolimus therapy", J Clin Pharmacol, 42, pp.798~805 (2002)
- Rodrigo E, "Within patient variability in tacrolimus blood levels predicts kidney graft loss and donor-specific antibody development", Transplantation, 100, pp.2479~2485 (2016)
- Knight SR, "Intrapatient variability in tacrolimus exposure-a useful tool for clinical practice?", Transpl Int, 29, pp.1155~1157 (2016)